The listed investment company considers ‘strategic options’.
ASX-listed sanitiser maker to defend accusations of making false representations about its products.
Automation and robotics company’s ownership structure strategic review still ongoing.
The US Food and Drug Administration has opened the door to a US$7b market.
Company apologises to disappointed shareholding travellers at today’s AGM.
Despite CEO Ross Taylor’s staunch defence of the company’s plumbing product, uncertainty remains about the causes and costs of a leaky pipe crisis in Australia.
After four long, difficult, expensive years since listing on the NZX, Cannasouth reckons it’s reached a turning point.
Saturday’s election result was broadly in line with expectations but a few sectors are primed to prosper under a change of government.
NZ-founded, ASX-listed chemicals group has lost its third director post-IPO.
Initial reaction strongly negative as market digests risks of Australian leaky pipes problem.
